Production (Stage)
Madrigal Pharmaceuticals, Inc.
MDGL
$278.23
$4.131.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 317.38M | 180.13M | 76.81M | 14.64M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 317.38M | 180.13M | 76.81M | 14.64M | -- |
| Cost of Revenue | 10.75M | 6.23M | 2.79M | 636.00K | -- |
| Gross Profit | 306.64M | 173.90M | 74.03M | 14.00M | -- |
| SG&A Expenses | 522.13M | 435.06M | 340.37M | 260.37M | 172.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 742.53M | 678.01M | 624.87M | 544.92M | 454.20M |
| Operating Income | -425.15M | -497.87M | -548.05M | -530.28M | -454.20M |
| Income Before Tax | -391.59M | -465.89M | -518.67M | -510.45M | -444.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -391.59 | -465.89 | -518.67 | -510.45 | -444.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -391.59M | -465.89M | -518.67M | -510.45M | -444.28M |
| EBIT | -425.15M | -497.87M | -548.05M | -530.28M | -454.20M |
| EBITDA | -423.84M | -496.78M | -547.18M | -529.57M | -453.63M |
| EPS Basic | -18.04 | -22.11 | -25.07 | -25.50 | -23.08 |
| Normalized Basic EPS | -11.28 | -13.82 | -15.67 | -15.94 | -14.43 |
| EPS Diluted | -18.04 | -22.11 | -25.07 | -25.50 | -23.08 |
| Normalized Diluted EPS | -11.28 | -13.82 | -15.67 | -15.94 | -14.43 |
| Average Basic Shares Outstanding | 87.17M | 85.08M | 82.91M | 79.64M | 76.55M |
| Average Diluted Shares Outstanding | 87.17M | 85.08M | 82.91M | 79.64M | 76.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |